TARIMAD – EEA grants

<< back

Norway grants

TARIMAD: Targeted and Improved Alzheimer’s Disease Drug Development
TARIMAD: Pokročilý vývoj léčiv na Alzheimerovu nemoc

EEA Norway grants funding for East European countries (via TACR)

2021-2024

Partners:
Jens Pahnke, University of Oslo (UiO), Norway
Ondřej Soukup, Fakultní nemocnice Hradec Králové, Czech Republic
MUDr. Peter Bauer Ph.D., Bioinova, Czech Republic
Mgr. Martin Horák Ph.D., Ústav experimentální medicíny AV ČR, v.v.i., Czech Republic

Objectives:
The aim of the project is the development of compounds for the treatment of Alzheimer´s disease
(AD). The project will include an approaches of personalized medicine during the development
process in the way that novel compounds will be tested in a disease in a dish (DiD) model derived
from AD patients.

Cílem projektu je vývoj sloučenin pro léčbu Alzheimerovy choroby (AD). Projekt bude zahrnovat
přístupy personalizované medicíny během vývojového procesu tak, aby nové sloučeniny byly
testovány na modelu disease-in-a-dish (DiD) odvozeného z pacientských vzorků.

Keywords: Alzheimer’s, drug development, ABC transporter

Resources / Links:
O. Soukup – read more….

Meetings:
Drug Discovery Conference in Riga, 21-24. Sep 2022

TransportDEMENTIA5 in Tromsø, 28. Aug – 1. Sep 2023

Posters at DDC2022 – Poster Prize to Katja Stefan (bottom left)

Selected References:

  • Physicochemistry shapes bioactivity landscape of pan-ABC transporter modulators: Anchor point for innovative Alzheimer’s disease therapeutics
    Int J of Biological Macromolecules (2022)

    Namasivayam V, Stefan K,Gorecki L, Korabecny J, Soukup O, Jansson PJ, Pahnke J, Stefan SM
    217:775-791 PubMed PDF